

CKR-2B (C-20): sc-6228

BACKGROUND

C-C or β chemokine family members are characterized by a pair of adjacent cysteine residues and serve as potent chemoattractants and activators of monocytes and T cells. C-C chemokine receptor family members include CKR-1, CKR-2A, CKR-2B, CKR-3, CKR-4, CKR-5, CKR-6, CKR-7, CKR-8, CKR-9, CKR-10 and the Duffy blood group antigen. Each of these receptors are G protein-coupled, seven pass transmembrane domain proteins whose major physiological role is to function in the chemotaxis of T cells and phagocytic cells to areas of inflammation. However, this receptor family has also been shown to facilitate viral infection. CKR-2 (C-C chemokine receptor type 2) is a 374 amino acid multi-pass membrane protein that belongs to the C-C chemokine receptor family and is expressed as 2 isoforms, designated CKR-2A and CKR-2B. Both CKR-2 isoforms function as receptors for a variety of proteins, including MCP-1 and MCP-3, thereby influencing intracellular calcium levels and affecting signal transduction throughout the cell.

CHROMOSOMAL LOCATION

Genetic locus: CCR2 (human) mapping to 3p21.31; Ccr2 (mouse) mapping to 9 F4.

SOURCE

CKR-2B (C-20) is an affinity purified goat polyclonal antibody raised against a peptide mapping at the C-terminus of CKR-2B of human origin.

PRODUCT

Each vial contains 200 μ g IgG in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin.

Blocking peptide available for competition studies, sc-6228 P, (100 μ g peptide in 0.5 ml PBS containing < 0.1% sodium azide and 0.2% BSA).

APPLICATIONS

CKR-2B (C-20) is recommended for detection of CKR-2B of human origin and CKR-2 of mouse, rat and human origin by Western Blotting (starting dilution 1:200, dilution range 1:100-1:1000), immunofluorescence (starting dilution 1:50, dilution range 1:50-1:500) and solid phase ELISA (starting dilution 1:30, dilution range 1:30-1:3000).

CKR-2B (C-20) is also recommended for detection of CKR-2B in additional species, including equine.

Suitable for use as control antibody for CKR-2 siRNA (h): sc-270220, CKR-2 siRNA (m): sc-44766, CKR-2 shRNA Plasmid (h): sc-270220-SH, CKR-2 shRNA Plasmid (m): sc-44766-SH, CKR-2 shRNA (h) Lentiviral Particles: sc-270220-V and CKR-2 shRNA (m) Lentiviral Particles: sc-44766-V.

Molecular Weight of CKR-2B: 41 kDa.

Positive Controls: Hep G2 cell lysate: sc-2227.

STORAGE

Store at 4° C, **DO NOT FREEZE**. Stable for one year from the date of shipment. Non-hazardous. No MSDS required.

SELECT PRODUCT CITATIONS

- de Boer, W.I., et al. 2000. Monocyte chemoattractant protein 1, interleukin 8, and chronic airways inflammation in COPD. *J. Pathol.* 190: 619-626.
- Shang, X., et al. 2000. Chemokine receptor 1 knockout abrogates natural killer cell recruitment and impairs type-1 cytokines in lymphoid tissue during pulmonary granuloma formation. *Am. J. Pathol.* 157: 2005-2063.
- Furuichi, K., et al. 2003. Gene therapy expressing amino-terminal truncated monocyte chemoattractant protein-1 prevents renal ischemia-reperfusion injury. *J. Am. Soc. Nephrol.* 14: 1066-1071.
- Furuichi, K., et al. 2003. CCR2 signaling contributes to ischemia-reperfusion injury in kidney. *J. Am. Soc. Nephrol.* 14: 2503-2515.
- Saiura, A., et al. 2004. Antimonocyte chemoattractant protein-1 gene therapy attenuates graft vasculopathy. *Arterioscler. Thromb. Vasc. Biol.* 24: 1886-1890.
- Wada, T., et al. 2004. Gene therapy via blockade of monocyte chemoattractant protein-1 for renal fibrosis. *J. Am. Soc. Nephrol.* 15: 940-948.
- Pluchino, S., et al. 2005. Neurosphere-derived multipotent precursors promote neuroprotection by an immunomodulatory mechanism. *Nature* 436: 266-271.
- Terashima, Y., et al. 2005. Pivotal function for cytoplasmic protein FROUNT in CCR2-mediated monocyte chemotaxis. *Nat. Immunol.* 6: 827-835.
- Ryschich, E., et al. 2006. Molecular fingerprinting and autocrine growth regulation of endothelial cells in a murine model of hepatocellular carcinoma. *Cancer Res.* 66: 198-211.
- Yrlid, U., et al. 2006. Relationships between distinct blood monocyte subsets and migrating intestinal lymph dendritic cells *in vivo* under steady-state conditions. *J. Immunol.* 176: 4155-4162.
- Vit, J.P., et al. 2006. The analgesic effect of low dose focal irradiation in a mouse model of bone cancer is associated with spinal changes in neuro-mediators of nociception. *Pain* 120: 188-201.
- Daugherty, A., et al. 2010. Angiotensin II infusion promotes ascending aortic aneurysms: attenuation by CCR2 deficiency in apoE^{-/-} mice. *Clin. Sci.* 118: 681-689.
- De Paepe, B., et al. 2012. Upregulation of chemokines and their receptors in duchenne muscular dystrophy: potential for attenuation of myofiber necrosis. *Muscle Nerve* 45: 914-916.

RESEARCH USE

For research use only, not for use in diagnostic procedures.

MONOS
Satisfaction
Guaranteed

Try **CKR-2B (A-11): sc-74490** or **CKR-2B (H-9): sc-74491**, our highly recommended monoclonal alternatives to CKR-2B (C-20).